Skin is an immunological organ with a delicate immunological network that governs the homeostasis and homing of the pro-and anti-inflammatory immune cells. Dysregulated immune response may result in psoriasis, a common inflammatory skin disease. Inappropriate immune surveillance, on the other hand, may cause the development of cutaneous lymphomas. Such homing of the immune cells likely depends on the interactions of chemokine and its receptors. Chemokine receptors and their corresponding chemokine ligands play key roles in the migration and localization of normal T cells in psoriasis and neoplastic T cells in cutaneous T-cell lymphoma (CTCL). While important in immune cell homing in psoriatic skin, chemokines and chemokine receptors may also be used for arrest, homing, and survival of neoplastic T cells in CTCL. In this review, we discuss roles of chemokine receptors, including those of CCR4 and CCR10 in the pathogenesis of CTCL, and of CCR6 in the pathogenesis of psoriasis. Targeting chemokines and chemokine receptors may lead to more effective treatments in these two skin diseases.
Introduction
Chemokines are small cytokines representing a large group of small chemotactic proteins (w8e11 kDa in size) that guide the movement of leukocytes to sites of inflammation. 1 They bind and activate cell-surface chemokine receptors, which belong to a large superfamily of seven-transmembrane-spanning, G-protein-coupled receptors. 1 Chemokines are categorized into four families (C, CC, CXC, and CX3C) according to the spacing of key cysteine residues near the N terminus of the chemokine. 1 Chemokines and their receptors are generally identified by their systematic names, consisting of the family of the chemokine followed by the letter R for receptor or L for ligand, with a number indicating their chronological order of discovery. The CC and CXC families comprise the majority of known chemokines. Redundancies are present in chemokineechemokine receptor interactions because certain chemokine receptors bind to multiple chemokines and vice versa. Engagement of chemokine receptors with cognate chemokines can activate several downstream intracellular signaling pathways, including calcium flux as well as phosphoinositide-3 kinase (PI3 K) and mitogen-activated protein kinase activation. Upon ligation of chemokine receptors, these cell signaling pathways result in diverse cellular processing such as cytoskeleton reorganization, cell locomotion, and prosurvival signaling. 2, 3 Chemokines, as chemoattractant factors, are known for their ability to stimulate directional migration of all classes of leukocytes. Diverse subsets of T cells, such as Th1, Th2, Th17, Treg, and memory T cells, express a regulated set of chemokine receptors that enable them to differentially respond to specific chemokines. In the skin, epidermal keratinocytes are able to express multiple chemokines that can attract certain leukocytes, such as T cells or dendritic cells (DCs), to migrate to the epidermis. In addition to their chemotactic activity, chemokines enhance the ability of rolling and adhesion of leukocytes to endothelial cells by increasing the affinity and avidity of b1 and b2 integrins on leukocytes in vitro and in vivo.
The skin provides a potent physical barrier and possesses a sophisticated immunological defense system. The skin immune system includes keratinocytes (being the most abundant cells in the epidermis), epidermal Langerhans cells (LCs), dermal DCs, T cells, endothelial cells, and fibroblasts. Keratinocytes are able to release several cytokines and chemokines both under baseline and under activated conditions. A delicate balance between pro-and anti-inflammatory signals is critical in maintaining the normal physiologic functions in the skin. Once disturbed and/or dysregulated, the immune system of the skin may contribute to various diseases because of defective tumor immunosurveillance, uncontrolled malignant T-cell growth, defective pathogen defense, and exaggerated autoimmune reactions. Herein we examine two diseases as examples where the roles for chemokines or their receptors have been demonstrated through human and experimental animal studies. First, mycosis fungoides (MF), a form of CTCL, is characterized by the invasion of epidermis (and dermis) with malignant T cells. Chemokines from keratinocytes, stromal cells, and endothelial cells contribute to the preferential homing, activation, and prosurvival of those malignant T cells. Second, psoriasis, a common dermatological disease that affects 2e3% of the world's populations and 0.1e0.5% of the Taiwanese populations, causes a significant morbidity in patients and is now known to be associated with comorbidities, including metabolic syndrome, obesity, and ischemic vascular disease. In psoriasis, dermal mixed inflammatory infiltrates and presence of neutrophils in the epidermis along with epidermal hyperproliferation are highly characteristic. Chemokines from various skin cells mediate trafficking of different subsets of inflammatory cells when binding to their corresponding receptors, forming a vicious proinflammatory circle. Selective expression of chemokine receptors in Th17 cells may provide good therapeutic targets in psoriasis.
Mycosis fungoides
Preface MF is the most common form of CTCL. Patients with patches and thin plaques usually have an indolent course. However, patients with thick plaques and tumors, often extensive, face a poor clinical prognosis. Sézary syndrome (SS) is a rarer leukemic variant of CTCL (compared to MF) with striking skin findings that include erythroderma as well lymphadenopathy. Malignant SS cells circulating in the bloodstream have cerebriform nuclei and lose normal T-cell surface receptors such as CD7 and CD26. MF is characterized by the invasion of epidermis with malignant T cells. Chemokines from keratinocytes, stromal cells, and endothelial cells contribute to the preferential homing, activation, and, possibly, survival of malignant T cells in both MF and SS. Recent work has indicated that MF and SS arise from distinct populations of memory T cells called skinresident T cells and central memory T cells, respectively. 4 
Role of chemokines and chemokine receptors in neoplasia
Cancer cells take advantage of their upregulated chemokine receptors to alter their organ-targeting metastatic spread. Mechanistically, chemokine receptors can regulate the ability of cancer cells to arrest on vascular endothelial cells. 5 Moreover, chemokine receptor engagement results in the activation of well-characterized prosurvival pathways such as PI3 K and Akt (also known as protein kinase B). 6 Melanoma cells could utilize CXCR4 and CCR10 to enhance cell survival and to escape killing in the absence of serum or in the face of immune attack. 7 CXCR4 inhibition renders those melanoma cells susceptible to immunotherapy with cyclophosphamide and adoptive T-cell transfer. 8 CCR10 activates PI3 K, which mediates the inhibition of T-cell-and Fas-dependent killing of melanoma cells in vitro. CXCR4 expression in basal cell carcinoma contributes to tumor invasiveness through dermal matrix remodeling 9 and angiogenesis. 10 In T cells, chemokine receptor activation suppressed the apoptosis induced by cyclohexamide or serum deprivation. 11, 12 Thus, besides the chemotactic functions to enhance metastasis, the prosurvival signals of chemokine receptors in the tumor cells may help these cells evade various forms of death induced by chemotherapy or immunotherapy ( Figure 1 ).
Skin microenvironment and homing of malignant T cells in MF
In skin, keratinocytes, the major cells in the epidermis, can release multiple chemokines. Those chemokines can attract a wide variety of leukocytes, including T cells, to the epidermis. Chemokines produced by other cells, namely epidermal LCs and dermal DCs bearing yet-unidentified skin antigens, may also play important roles in attracting and activating malignant T cells (Figure 1 ). Studies have found that DCs synthesize CCR4 ligands, which rapidly promote migration of normal T cells. 13, 14 A histopathological feature of MF, Pautrier's microabscesses, represents DC-malignant T-cell conjugates that may result from these DC-derived chemokines. Involvement of DC in CTCL pathophysiology has already been extensively reviewed. 15 Individual chemokines that may play a role in CTCL
In peripheral blood, only w25% of circulating T cells express CCR4. 16 By contrast, MF as well as SS cells have increased CCR4 expressions. 16 ,17 CCL17, a CCR4 ligand, is produced by activated keratinocytes, endothelial cells, and DCs. Interestingly, CCL17 is upregulated in the epidermis and serum of MF patients. 18 The increased CCL17
in the skin may result in the preferential homing of MF cells to the skin or aid in the survival of pre-existing skin-resident malignant T cells. Clinically, increased CCL17 in blood may be a useful marker to monitor the disease progression and treatment response in MF. 19 Similarly, CCR10, which binds to CCL27 ligand, is only infrequently expressed on peripheral blood T cells, but it is considerably enhanced in cutaneous lymphocyte antigen (CLAþ) skin-homing T cells and in CTCL cells. 20, 21 Analogous to CCL17 (a CCR4 ligand), CCL27 (a CCR10 ligand) is increased in the serum of MF/SS patients and may serve as a biomarker of disease activity 22 and a therapeutic marker after IFN-g and PUVA therapy. 23 CCL27 is constitutively synthesized in basal keratinocytes and is somewhat enhanced under proinflammatorysituations. Thus, CCL27 may play a role in T- cell epidermotropism in MF. Not only CCL27 can regulate cutaneous homing, but it can also regulate nodal homing of T cells by rapidly being released from activated keratinocytes to regional lymph nodes via afferent lymphatics.
24
CCR7 is critical for migration of maturing skin DCs and selected T-cell subsets to the cutaneous draining lymph nodes. 25 CCR7 is found to be expressed atquite high levels in SS cells 26 and may play a role in the tropism of these cells to peripheral lymph nodes, which constitutively synthesize the corresponding CCR7 ligand, CCL21. Keratinocytes, endothelial cells, and dermal fibroblasts in lesionalskinof CTCL showed stronger expression of eotaxin-3 than did normalskin. CCR3(þ) lymphocytes were observed in some cases of advanced CTCL. Both serum eotaxin-3 and eotaxin-1 levels of CTCL patients at advanced stages were significantly higher than those of healthy individuals. The study suggested that interaction of eotaxins and CCR3 may regulate the Th2-dominant tumor environment, which is common in CTCL.
27
CXCR4 may also be a crucial chemokine in homing of MF and SS cells to skin. Loss of the cell-surface antigens, such as CD7 and CD26, is a characteristic feature in MF and SS. 28 Downregulation of CD26, a dipeptidylpeptidase, is interesting in particular, since CD26 cleaves the critical amino terminus of several chemokines, including CXCL12, and rapidly deactivates this chemokine in terms of its ability to activate through CXCR4. Inactivation of CD26 promoted CXCL12-driven chemotaxis of cell lines derived from SS patients. 16 On the other hand, soluble CD26 was shown to inhibit CXCR4-mediated migration. Thus, loss of CD26 on the SS cells may provide a mechanism for their increased migration and survival in the skin.
Further mechanistic and applied insights with respect to CCR4 and CCR10 in MF CCR4 and CCR10 share similarities in their ability to direct the trafficking of T cells to the skin under inflammatory conditions. 29, 30 Both receptors are selectively expressed by "skin-homing" memory T cells that bear surface carbohydrate ligands to E-selectin, an adhesion protein that is characteristically expressed by inflamed dermal blood vessels. Neutralizing antibodies to CCL27 (the CCR10 ligand) reduced inflammation significantly in a mouse model of contact dermatitis. 30 The role of CCR4 and its ligand CCL17, however, is less clear because optimal inhibition of cutaneous inflammation in CCR4-deficient mice required simultaneous administration of CCL27 antagonists. 29 Recent studies indicated that CCR4 is crucial in the antigen-dependent skin inflammation, as evidenced by the failure to accumulate ovalbumin (OVA)-specific T cells in the skin. 31 The facts that T-cell activation is achieved by the adoptive transfer of CCR4-defected OVA-specific T cells and that CCR4-negative T cells home inefficiently to skin, but normally to the gut, suggested a trafficking defect to the skin as opposed to an intrinsic homing defect in these cells. 31 Besides the in vitro and animal studies, several clinical observational studies suggest that CCR4 is generally very highly expressed among CTCL cells in MF and SS patients (Table 1) . 16,20,21,25,31e38 Targeting CCR4 and CCR10, the two chemokine receptors that are often expressed by CTCL cells, may be an attractive therapeutic approach to treat CTCL. Since normal circulatory T cells also express those two receptors, it remains unknown whether targeting these two receptors would result in unwanted immunosuppression. Nevertheless, a relatively small portion of the total Tcell population expresses these two receptors. Thus, obliteration of CCR4-and CCR10-positive T-cell populations would not likely result in severe lymphopenia. Small-molecule antagonists of CCR4 and CCR10 (as present in CXCR4) have yet to be developed, but antibodies targeting CCR4 that induce antibody-dependent cellular cytotoxicity have already been reported. 39, 40 The humanized anti-CCR4 antibody has been approved for use in Japan for adult T-cell leukemia/lymphoma (ATLL). Furthermore, bexarotene was reported to inhibit functional activation of CCR4, suggesting a potential mechanism through which bexarotene is effective in CTCL. 41 Analogous to interleukin-2 (IL-2)ediphtheria toxin fusion protein (denileukin diftitox), novel chemokineetoxin fusion proteins may selectively target skin-homing T-cell populations if they utilized chemokines such as CCL17 or CCL27 to direct ligation to cutaneous T cells ( Figure 1 ). Selective binding of the chemokine receptor with a fusion toxin would result in endocytosis of the chemokineetoxin and subsequent cell killing. CCL17 molecules fused to the Pseudomonas exotoxin 38 have already been shown to eliminate successfully the lymphoma cells that express CCR4. 42 Therefore, chemokineetoxin fusion proteins may be useful as therapeutic agents in MF and/or SS. 
Short summary
Chemokine receptors are likely to be involved in the selective skin homing that characterizes CTCL. In addition to assisting in the firm arrest of skin-homing T cells on dermal vascular endothelial cells, they provide directional signals for T cells to migrate to specific compartments of the skin, including the epidermis. Even after localizing in skin, chemokine receptors may increase the survival of the malignant T cells through activation of prosurvival pathways such as PI3 K and Akt. The understanding of how chemokine receptors participate in trafficking and survival provides a promising rationale for the use of receptor inhibitors or antichemokine receptor antibodies as novel therapeutic agents.
Psoriasis

Clinical manifestations of psoriasis
Psoriasis can be subdivided into several clinical subtypes: guttate, inverse, palmoplantar, plaque, and erythrodermic psoriasis. Each subtype has its own anatomic predilections, response to therapy, and genetic signatures. Guttate psoriasis presents with small and scaly papules, usually with a preceding streptococcal infection.
Inverse psoriasis tends to affect folds of the body, including the axilla, umbilicus, and inguinal creases. Plaque psoriasis is the most common subtype of psoriasis, characterized by red, welldemarcated plaques covered with a silvery scale often involving the extensor aspects of the body skin (Table 2) . 20,43e63 Histologically, in epidermis, often parakeratosis and occasionally neutrophil accumulation occur in the subcorneal layer, known as subcorneal pustules of Kogoj. The granular layer is often absent, and there are usually striking epidermal acanthosis and a regular elongation of the rete ridges. The suprapapillary plates are thin, making the dilated dermal vessels occasionally grossly visible.
Recent studies have demonstrated that the skin is home to tens of millions of resident effector memory T cells. 64 Even under clinical resolution in psoriatic plaques, a genetic signature of psoriasis and its proinflammatory state, a so-called "residual disease genomic profile," remains. 65 Palmoplantar psoriasis may thus arise because the hands and feet are constantly traumatized. A better understanding of the individual genetic signatures in the skin microenvironment may provide more precise targets for treatment in the future. 73 These studies show that the number of Th17 cells and downstream effecter molecules, IL-17A, IL-17F, tumor necrosis factor (TNF)-a, and IL-22 are increased in psoriatic skin lesions. 73 Roles of different CD4 þ T-cell subsets in psoriasis are shown in Figure 2 . Circulating Th17 cells in adult human blood express CCR2, CCR4, CCR5, CCR6, and CXCR3. 67 Among those, CCR6 has been described as a marker for Th17 cells both in human and in murine T cells. 74 Due to the paradigm shift to Th17 in psoriasis, several recent studies have focused on the role of CCR6 in the pathophysiology of psoriasis. CCR6 was initially discovered on both T cells 75 and immature DCs. 76, 77 Recently, several research groups have shown that CCR6 plays an important role in the Th17 signaling pathway 2 and in the pathogenesis of psoriasis (as described below). CCR6 was initially shown to mediate adhesion and arrest of T cells to endothelial cells under physiologic shear stress. 78 In psoriatic patients, peripheral CCR6-expressing Th17 cells are increased both in skin and in blood. 52 Moreover, current models suggest that IL-23
CCR6 and CCL20 in psoriasis
from DCs maintain dermal CCR6-expressing Th17 cells. 79 CCR6
appears to be essential for the development of a psoriasiform phenotype in mice since IL-23 injection in skin of WT mouse, 80 but not in that of CCR6 knockout mice, results in psoriasis-like skin lesions, 80 indicating that CCR6 chemokine axis may be a provisional target in psoriasis. 66 Of note, anti-CCR6 antibody reduced the severity of collagen-induced arthritis, a model for rheumatoid arthritis. 81 While no small-molecule inhibitors of CCL20 or CCR6 have yet been described, new in silicotechniques 82 that have successfully identified drug-like CXCR4/CXCL12 antagonists 83 may soon allow the rational design of CCR6/CCL20 antagonists.
CCL20 and psoriasis CCL20 is the only known chemokine ligand for CCR6 84 ; however, human b-defensin 2 (hBD2) also induces chemotaxis of leukocytes via CCR6. 85 CCL20 is constitutively expressed at low levels in epidermal keratinocytes and dermal endothelial cells. 84 Its expression is strongly enhanced by proinflammatory cytokines, including TNF-a, IL-1a, IL-17, and IFN-g. 78, 84 In psoriatic skin lesions, CCL20 is robustly expressed throughout the epidermis 52, 66 and may be crucial in recruiting CCR6-expressing T cells into inflamed epidermis from underlined dermis, whereas CCL20 expressed by dermal endothelial cells may serve to arrest CCR6-positive leukocytes from the blood stream. Furthermore, production of CCL20, which is enhanced by CCR6 þ Th17 cells producing IL-17, positively reinforces the recruitment of more CCR6 þ Th17 cells (Figure 3 ).
Other chemokines that may possibly be involved in psoriasis
Neutrophils and CXCL8 CXCL8, a neutrophil chemoattractant (chemokine), is notably increased in psoriatic skin by quantitative polymerase chain reaction (qPCR).
T cells and CCR10
Analogous to that occurs in MF, more than 90% of the T cells in psoriatic skin expresses CCR10, a receptor for the chemokine ligand CCL27 that is constitutively expressed in the epidermis. TNFaupregulates CCL27 expression in keratinocytes both in mice and in humans, and therefore recruits more effector memory T cells to the skin. 20 
DCs and CCR6
In addition to T cells, LCs also express CCR6 87 and are strongly migrate toward CCL20. 87 Komine et al 88 showed that the number of CD1aþCD11cþlangerinþ DCs in lesional skin was increased compared with those in uninvolved skin. CD11cþ mature DCs harvested from the dermis of psoriatic skin lesions generate IL-23, 89 a key factor that maintains Th17 differentiation. Another subset of dermal DCs, TNF/iNOS-producing DCs, 86 also plays a role in the development of psoriasis through production of IL-20.
90,91
Besides DCs, dermal macrophages show increased expression of CCR2, 44 CCR5, 48 and CXCL9 46, 61 in psoriatic skin lesions. CCR6 may not be present on mature macrophages; however, it may be involved in the development of macrophage lineage. 92 Of note, in Rag1-deficient mice, which lack both T and B cells, IL-23 injection in the first 5e6 days of treatment (but not after that) resulted in a psoriasiform skin phenotype along with production of IL-22 and IL-17A, suggesting that T cells are not essential in the initial responses to IL-23. 66 Therefore, LCs, DCs, and macrophages may also be able to induce psoriasis-like features initially in the absence of T cells, although it appears that expression of T cells is required to maintain expression of IL-17A and IL-22 after initial induction of psoriasiform dermatitis. 66 Role of gd T cells in psoriasis While there appears to be a convincing role for conventional abT cells in psoriasis, the role of unconventional T cells, including gd T Figure 3 Roles of chemokines and chemokine receptors in psoriasis. Circulating CCR4-and CXCR3-expressing Th1 cells migrate into epidermis from dermis through interaction with KC-derived CCL17 and/or CCL22, the CCR4 ligands, and CXCL9, CXCL10, and/or CXCL11, the CXCR3 ligands. CCR5-expressing CD3 þ T cells move to epidermis via interaction with CCL3 and KC-derived CCL5, both CCR5 ligands. The selectivity of CCL20 for CCR6 allows recruitment of circulating CCR6-expressing cells, including Th17 cells and gdT cells that express Th17 cytokines, as well as LCs into inflamed epidermis.
CCR10-expressing CLAþ, CD4þ, and CD8 þ T cells migrate into epidermis via KCderived CCL27, the CCR10 ligand. CXCL8 is a common ligand for both CXCR1 and CXCR2, and is a potent chemoattractant for neutrophils. CCR2-expressing monocytes and Mfs migrate into epidermis via KC-derived CCL2, the CCR2 ligand. The pDCs, which also express CXCR3, also migrate toward inflamed epidermis. CLA ¼ cutaneous lymphocyte antigen; EC ¼ endothelial cell; KC ¼ keratinocyte; LC ¼ Langerhans cell; Mf ¼ macrophage; pDC ¼ plasmatoid dendritic cell. 99 raising the possibility that drugs or antibodies targeted at the CCR6/CCL20 axis may be therapeutically beneficial in psoriasis or other Th17-mediated autoimmune disease. 80 
Role of b-defensin 2 in psoriasis
In addition to CCL20, hBD2 also signals through CCR6. 85 Defensins are small (3.5e4.5 kDa in size) antibacterial peptides that are primarily expressed by epithelial cells in the skin, kidney, and tracheaebronchial lining. Defensins exhibit a broad spectrum of antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, and viruses. The defensin hBD2 is highly expressed in the epidermis of psoriatic skin. 100 Increased copy numbers of bdefensin gene are associated with susceptibility to psoriasis in Dutch and German populations, 101 and serum levels of hBD2 may be a useful marker for disease activity in psoriasis. 100 Increased hBD2 production in psoriasis may act in concert with CCL20 to attract requisite populations of CCR6þ cells, including Th17 cells.
CXCR3 in dermal CD3þ lymphocytes
CXCR3 is upregulated on dermal CD3þ lymphocytes. The corresponding ligands CXCL9, CXCL10, and CXCL11 (also known as Mig, IP10, and ITAC, respectively) are increased in psoriatic skin lesions. 45, 59 CXCR3 is involved in transendothelial migration of T cells and T-cell trafficking to psoriatic epidermis.
45
CCR5 in epidermal T cells and dermal macrophages CCL5, or RANTES, one of the ligands for CCR5, is highly expressed in psoriatic skin lesions. 49, 51 Calcipotriol, an active vitamin D3
analogue, can inhibit CCL5 production in cultured normal epidermal keratinocytes. 49 Furthermore, CCR5 expression was considerably higher in both epidermal T cells and dermal macrophages in lesional psoriatic skin comparing to that measured in nonlesional skin. 48 Although these results suggested a potential role for CCR5 and CCL5 in the inflammatory cascade of psoriasis, the CCR5 inhibitor SCH51125 yielded neither clinical benefit nor significant differences in CCR5 expression during psoriasis clinical trials. 48 Therapeutic targets of chemokines and chemokine receptors in psoriasis CXCR3 small-molecule antagonist T487 The CXCR3 small-molecule antagonist T487 was found to relieve symptoms and hinder the progression of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis. 102 Although a phase II trial of T487 in psoriasis was performed in 2003, 103 its use in psoriasis has not been reported since that time.
CXCL8 humanized neutralizing monoclonal antibody ABX-IL8 CXCL8 (also known as IL-8), a common ligand for CXCR1 and CXCR2, represents a potent chemoattractant for neutrophils. It likely plays a role in recruitment of neutrophils to the epidermis and cornified layer, leading to Munro abscesses, a characteristic feature in psoriasis. ABX-IL8 is a fully humanized neutralizing monoclonal antibody against CXCL8 that was evaluated in a phase II clinical trial for psoriasis. However, ABX-IL8 was not effective in reducing PASI scores. 102 While the reason for the lack of clinical effect is unclear, this might have resulted from the presence of other redundant neutrophil-attracting CXCR1/CXCR2 ligands such as CXCL1, CXCL2, CXCL3, CXCL5, and CXCL6. 80 
Short summary
Multiple chemokines and chemokine receptors maybe involved in the development and progression of psoriasis. The redundancy of the chemokine system makes therapies targeting single chemokine or chemokine receptor challenging. However, in mouse models of psoriasis, therapeutic agents inhibiting the CCR6 pathway have demonstrated efficacy. Moreover, the mice lacking CCR6 are remarkably resistant to induction of psoriatic phenotype following IL-23 injection. Both CCL20 and hBD2 may recruit CCR6-expressing cells into inflamed epidermis. Given the possibility that these two peptides redundantly recruit inflammatory cells via CCR6, targeting CCR6 itself rather than its ligands, CCL20 or hBD2, with a monoclonal antibody or small molecule would seem to be a better targeting strategy in psoriasis.
Conclusion
Chemokines and chemokine receptors have long been recognized for their chemotactic activities with respect to many leukocytes, including Th1 cells, Th17 cells, macrophages, DCs, neutrophils, etc. Many of those chemokines and chemokine receptors are present in psoriatic skin and contribute to dermal inflammation and, perhaps indirectly, to epidermal keratinocyte hyperplasia in psoriasis. Preferential expression of CCR6 in Th17 cells makes CCR6 a rational therapeutic target in psoriasis. In neoplastic CTCL, malignant T cells proliferate, accumulate, and "home" to the skindprocesses that likely result from increased expression of chemokine receptors such as CCR4 and CCR10 in neoplastic T cells. Not only interactions of chemokines and chemokine receptors direct trafficking in those neoplastic cells, but those cells may also take advantage of the chemokine pathways to provide prosurvival signals and evade apoptosis by various assaults. The recent approval of an anti-CCR4 antibody for ATLL in Japan that has efficacy in CTCL provides definitive evidence that targeting chemokine receptors in neoplastic diseases can have clinical utility. Further attempts are warranted to identify CCR6 (and possibly other chemokine receptor) antagonists that may be useful in psoriasis and other autoimmune skin diseases. 
